Article
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Oct 2024
Di Federico A, Alden S L, Smithy J W, Ricciuti B, Alessi J V, Wang X, Pecci F, Lamberti G, Gandhi M M, Vaz V R, Spurr L F, Sholl L M, Pfaff K L, Rodig S J, Li Y Y, Cherniack A D, Nishino M, Johnson B E, Awad M M
Abstract excerpt
BACKGROUND: Programmed death receptor ligand 1 (PD-L1) tumor proportion score (TPS) and tumor mutational burden (TMB) are key predictive biomarkers for immune checkpoint inhibitor (ICI) efficacy in non-small-cell lung cancer (NSCLC). Data on their variation across multiple samples are limited. PATIENTS AND METHODS: Patients with NSCLC and multiple PD-L1 TPS and/or TMB assessments were included. Clinicopathologic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.